



NOVARTIS

4D Pharma

Pipeline • Products • Performance • Potential

CONTENTS

Latest Results	2
EXECUTIVE SUMMARY	5
Introduction	5
Current Financial Position	6
Company Performance 2007	6
Business Segment Performance	8
Geographic Segment Performance	11
Company Strategy	14
Mergers, Acquisitions and Divestitures	15
Key Agreements.....	18
Research and Development	19
Employees.....	20
Product Performance Forecasts	23
Pipeline Analysis	26
Discontinued Projects	27
Conclusions.....	28
THERAPEUTIC AREA FOCUS.....	31
R&D PIPELINE	33
CARDIOVASCULAR AND METABOLISM.....	36
Marketed Products	36
Diovan/Co-Diovan	36
Exforge	41
Galvus.....	43
Lescol.....	45
Lotrel	48
Tekturna/Rasilez	51
R&D Projects.....	57
ACZ885	57
HGH191	57
LCI699.....	57
LCZ696.....	57
SBR759	57
VNP489	57
Growth Forecast.....	58
ONCOLOGY/HAEMATOLOGY	60
Marketed Products	60
Exjade.....	60
Femara	62
Glivec/Gleevec	66
Sandostatin.....	76
Tasigna	78
Zometa	80
R&D Projects.....	85
AEE788	85
ASA404	85
AT9311	87
AUY922	87
BEZ235	87
BHQ880	87

Gimatecan (LBQ707)	87
HCD122	87
LBH589.....	88
LBQ707.....	88
LBY135.....	88
Midostaurin.....	88
Pasireotide (SOM230)	88
Patupilone	88
RAF265.....	88
TKI258	88
Xyotax	89
Growth Forecast.....	90
NEUROSCIENCE	92
Marketed Products	92
Comtan	92
Exelon	94
Extavia.....	98
Ritalin/Focalin	99
Stalevo	103
Trileptal.....	105
Others	108
R&D Projects.....	109
AFQ056.....	109
AQW051.....	109
ATI355.....	109
BAF312	109
BGG492.....	109
CAD106.....	109
Fingolimod.....	110
KRP203.....	112
SAB378.....	112
Valdoxan	112
Growth Forecast.....	114
OPHTHALMICS/DERMATOLOGY/ GASTROINTESTINAL/UROLOGY	115
Marketed Products	115
Elidel	115
Lamisil	118
Lucentis	121
Zelnorm/Zelmac	123
Others	126
R&D Projects.....	128
ACZ885	128
AEB071	128
AIN457	129
BCT194.....	129
DNK333.....	129
Rebamipide.....	129
SAD448.....	129
Y39983	129
Growth Forecast.....	130

Ophthalmics	130	NVA237	170
Dermatology	130	QAE397	171
Gastrointestinal	130	QAT370.....	171
Urology.....	130	QAU145.....	171
INFECTIOUS DISEASES/TRANSPLANTATION/ IMMUNOLOGY	131	QAX028.....	171
Marketed Products	131	QAX576.....	171
Certican	131	VAK694.....	171
Sandimmun/Neoral	135	Growth Forecast.....	172
Sebivo/Tyzeka	138	APPENDIX 1 - FINANCIAL PERFORMANCE	175
Others	140	Full Year Results 2007	175
R&D Projects.....	141	APPENDIX 2 - KEY AGREEMENTS.....	178
AEB071	141	Ablynx.....	178
AHT956	141	Alfacell Corporation	178
Albuzeron (ABF656)	141	Allergan	178
Aurograb.....	144	Alnylam Pharmaceuticals.....	179
IC51	144	Anadys Pharmaceuticals Inc.....	180
MenB.....	144	Antisoma plc.....	181
Menveo.....	145	APT Pharmaceuticals	182
Mycograb.....	145	Ardana plc.....	182
NIM811	146	Arrow Therapeutics Ltd	182
RSV604.....	146	Astex Therapeutics Ltd.....	183
Tifacogin.....	146	AstraZeneca	183
Valopicitabine	146	Avanir Pharmaceuticals Corporation	183
Valtorcitabine	148	Avalon Pharmaceuticals	184
Growth Forecast.....	149	Bausch & Lomb Inc	184
Infectious Diseases.....	149	Beijing Med-Pharm Corp.....	185
Infectious Diseases.....	149	Broad Institute / Harvard University.....	185
Transplantation/Immunology.....	149	Bayer Schering Pharma.....	185
ARTHRITIS/BONE.....	151	Biovail Corporation	186
Marketed Products	151	Celgene Corporation.....	187
Aclasta/Reclast.....	151	Cell Genesys Inc	188
Miacalcic/Miacalcin	156	Cell Therapeutics Inc.....	188
Voltaren/Cataflam.....	158	Cerimon Pharmaceuticals Inc	189
Others	160	Clinical Data Inc.....	189
R&D Projects.....	161	Conor Medsystems Inc.....	190
ACZ885	161	Cytos Biotechnology AG	190
ATF936	161	Cytosia Ltd	191
QAL964	161	Dynavax Technologies Corp.....	192
PTH (1-34).....	161	Elan Corporation plc.....	192
Growth Forecast.....	162	Emisphere Technologies Inc.....	193
RESPIRATORY	163	Endo Pharmaceuticals	195
Marketed Products	163	Galapagos NV	195
Foradil	163	Genelabs Technologies	195
Xolair.....	165	Genentech	196
Others	167	Gilead Sciences Inc	196
R&D Projects.....	168	Human Genome Sciences (HGS).....	197
ACZ885	168	Idenix Pharmaceuticals Inc.....	197
ACZ885	168	Idera Pharmaceuticals Inc	198
Indacaterol	169	Immusol Incorporated	199
NIC002.....	170	Infinity Pharmaceuticals Inc	200
		Intercell AG	201

IVAX Corporation	201
Kyorin Pharmaceutical Co Ltd	202
Massachusetts Institute of Technology	202
Meda AB	202
Medarex Inc	203
Medivir AB	204
Merck KGaA	204
MicroDose Technologies Inc	204
Mitsubishi Tanabe Pharma Corporation	204
Molecular Insight Pharmaceuticals Inc (MIP)	205
MorphoSys AG	205
NexMed Inc	207
Ono Pharmaceutical Co Ltd	207
Orion Corporation	207
Otsuka	208
QLT Inc	208
Radius Health Inc	209
Reliant Pharmaceuticals Inc	210
Saegis Pharmaceuticals Inc	210
sanofi-aventis	210
Schering-Plough	212
Senju Pharmaceutical Co Ltd	213
Servier	213
Sigma-Tau	213
SGX Pharmaceuticals Inc	213
SkyePharma PLC	214
Takeda	215
Tanox Biosystems Inc/Genentech Inc	215
TopoTarget AS	217
Valley Forge Pharmaceuticals Inc	217
Vectura Group plc/Arakis Ltd	217
Vernalis plc	217
Xenon Pharmaceuticals Inc	218
XOMA Ltd	219
APPENDIX 3 - INFRASTRUCTURE.....	220
Research and Development Facilities	220
Manufacturing Facilities.....	221
APPENDIX 4 - KEY PHARMACEUTICAL	
SUBSIDIARIES / JOINT VENTURES	222
Subsidiaries	222
APPENDIX 5 - PRODUCT INDEX	225

INDEX OF TABLES

<i>Principal Operating Results.....</i>	<i>1</i>
<i>Capital Expenditure By Business Area.....</i>	<i>6</i>
<i>Capital Expenditure By Geographical Area</i>	<i>7</i>
<i>Research And Development Expenditure By Business Area.....</i>	<i>8</i>
<i>Sales By Business Area</i>	<i>10</i>
<i>Operating Income By Business Area.....</i>	<i>11</i>
<i>Total Assets By Business Area.....</i>	<i>11</i>
<i>Sales By Destination</i>	<i>12</i>
<i>Operating Income By Geographical Area.....</i>	<i>13</i>
<i>Total Assets By Destination</i>	<i>13</i>
<i>Employees By Business Area (Year End).....</i>	<i>21</i>
<i>Employees By Geographical Area (Year End)</i>	<i>22</i>
<i>Recent Product Approvals</i>	<i>25</i>
<i>Major Products, Therapeutic Areas and Sales.....</i>	<i>31</i>
<i>Major Cardiovascular Products, 2007.....</i>	<i>36</i>
<i>Major Oncology/Haematology Products, 2007</i>	<i>60</i>
<i>Major Neuroscience Products, 2007.....</i>	<i>92</i>
<i>Major ODGU Products, 2007</i>	<i>115</i>
<i>Major IDTI Products, 2007.....</i>	<i>131</i>
<i>Major Arthritis/Bone Products, 2007.....</i>	<i>151</i>
<i>Major Respiratory Products, 2007</i>	<i>163</i>
<i>Foradil Sales (2002A-2012E)</i>	<i>165</i>
<i>Major Pharmaceutical Research & Development Facilities</i>	<i>220</i>
<i>Major Pharmaceutical Production Facilities</i>	<i>221</i>

INDEX OF CHARTS

<i>Capital Expenditure By Business Area, 2007</i>	6
<i>Capital Expenditure By Geographical Area, 2007</i>	7
<i>Research And Development Expenditure By Business Area, 2007</i>	8
<i>Sales By Business Area</i>	10
<i>Operating Income By Business Area</i>	11
<i>Sales By Destination</i>	12
<i>Operating Income by Geographic Area</i>	13
<i>Employees By Business Area, 2007</i>	21
<i>Employees By Geographical Area (Year End), 2007</i>	22
<i>Forecast Sales of Major Products (2002A-2012E)</i>	24
<i>Top Selling Products, 2007</i>	32
<i>Diovan/Co-Diovan Product Sales (2002A-2012E)</i>	40
<i>Exforge Sales (2002A - 2012E)</i>	42
<i>Galvus Sales (2008E - 2012E)</i>	44
<i>Lescol Sales (2002A-2012E)</i>	48
<i>Lotrel Sales (2002A-2012E)</i>	50
<i>Tekturma Sales (2002A - 2011E)</i>	53
<i>Exjade Sales (2002A-2012E)</i>	62
<i>Femara Sales (2002A-2012E)</i>	64
<i>Glivec/Gleevec Sales (2002A-2012E)</i>	73
<i>Sandostatin Sales (2002A-2012E)</i>	77
<i>Tasigna Sales (2008E - 2012E)</i>	79
<i>Zometa Sales (2002A-2012E)</i>	83
<i>Stavelo/Comtan Sales (2002A-2012E)</i>	93
<i>Exelon Sales (2002A-2012E)</i>	97
<i>Extavia Sales (2008E-2012E)</i>	99
<i>Ritalin Sales (2002A-2012E)</i>	102
<i>Stavelo/Comtan Sales (2002A-2012E)</i>	104
<i>Trileptal Sales (2002A-2012E)</i>	107
<i>Fingolimod (2009E - 2013E)</i>	111
<i>Valdoxan Sales (2009E-2013E)</i>	113
<i>Elidel Sales (2002A-2012E)</i>	118
<i>Lamisil Sales (2002A-2012E)</i>	121
<i>Lucentis Sales (2002A-2012E)</i>	123
<i>Sandimmun/Neoral Sales (2002A-2012E)</i>	138
<i>Tyzeka Sales (2008E-2012E)</i>	139
<i>Aclasta/Reclast Sales (2002A-2012E)</i>	154
<i>Miacalcic Sales (2002A-2012E)</i>	158
<i>Voltaren Sales (2002A-2012E)</i>	160
<i>Xolair Sales (2002A - 2012E)</i>	167
<i>Sales, Costs and Operating Income</i>	176
<i>Profitability and Research Ratios</i>	176
<i>R&D Expenditure and Capital Expenditure</i>	176
<i>Current Assets, Liabilities and Ratio</i>	177
<i>Assets, Cash and Liquidity</i>	177
<i>Employees and Productivity</i>	177